GPR119: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD

It's the GeneMedi's summary page for Target/Biomarker Introduction of GPR119. The page also collects GeneMedi's different modalities and formats products for GPR119 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the GPR119 target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Transmembrane Protein.

This gene encodes a member of the rhodopsin subfamily of G-protein-coupled receptors that is expressed in the pancreas and gastrointestinal tract. The encoded protein is activated by lipid amides including lysophosphatidylcholine and oleoylethanolamide and may be involved in glucose homeostasis. This protein is a potential drug target in the treatment of type 2 diabetes.[provided by RefSeq, Jan 2010]

Target IDGM-T93788
Target NameGPR119
Gene ID139760,236781,302813,703368,492134,101083248,524232,100054460
Gene Symbol and SynonymsGPCR2,GPR119
Uniprot AccessionQ8TDV5,Q7TQN8
Uniprot Entry NameGP119_HUMAN,GP119_RAT
Protein Sub-locationTransmembrane Protein
CategoryTherapeutics Target
DiseaseN/A
Gene EnsemblENSG00000147262
Target ClassificationGPCR


Pre-made anti-GPR119 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research

Pre-made anti-GPR119 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-GPR119 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Antibody NameSpeciesFormatClassified by tagDetail
Anti-GPR119 monoclonal antibodyHuman, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, EquinemabFACS/Biofunctional Antibody, Therapeutics Target antibodyDetail



Multi-species GP119/ GPR119/ GPCR2 VLP (virus-like particle) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine GPR119 VLP (virus-like particle) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.

Products NameSpeciesExpression PlatformDetail
GPR119 VLP (virus-like particle)Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, EquineMammalian cellProducts Developing






GENEMEDI
Email: [email protected]   [email protected]
Telephone: +86-21-50478399   Fax: 86-21-50478399
Privacy Policy
<